Nick Scali Ltd (NCK)
Australian Securities Exchange · Australia · prices in AUD · close of 22 Oct 2026
Key indicators
| Last close | AUD 12.03 |
|---|---|
| 52-week range | 10.93 – 26.08 |
| Return, 1 month / 3 months | −13.2% / −19.3% |
| Return, 1 year / 3 years | −42.2% / +26.3% |
| Trend | Below its 200-day average |
| RSI (14) | 25 |
| Volatility (1 year) | 44.8% |
| Worst drawdown (1 year) | -50.9% |
| Average daily value traded | 6.21M AUD |
| Dividend yield | 6.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Nick Scali Ltd is an Australian furniture retailer that runs a chain of showrooms offering lounges, sofas and other upholstered furniture for the home. The company sells its own imported ranges, mainly leather and fabric seating, to retail customers through its stores in Australia and New Zealand. It is based in Australia and serves households looking for living room furniture, with a focus on lounge suites and related pieces sold directly to consumers.
On this site Nick Scali Ltd appears as a stock on the Australian Securities Exchange (Australia), code NCK, with prices in Australian dollars (AUD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Nick Scali Ltd (NCK) trades on the Australian Securities Exchange in Australia. It last closed at AUD 12.03 on 22 October 2026.
Its price-based Market X-Ray is 54 out of 100 (a fair price profile), ranking 819 of 1,816 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 42.2% and over the last three months it fell 19.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 37 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -24.9% | ||
| From 52-week high | -53.2% | ||
| Momentum | 36 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -19.3% | ||
| 6-month return | -19.1% | ||
| 12-month return, skipping the last month | -33.4% | ||
| Stability (higher is calmer) | 65 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 44.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -50.9% | ||
| Liquidity | 89 · Strong | Trades actively. | |
| Average daily value traded | 6.21M AUD | ||
| Zero-volume days | 0.0% | ||
| Income | 62 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 6.5% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −15.8% |
|---|---|
| 1 month | −13.2% |
| 3 months | −19.3% |
| 6 months | −19.1% |
| 1 year | −42.2% |
| 3 years | +26.3% |
| 5 years | +7.0% |
Signals
| 50-day / 200-day average | 14.22 / 16.02 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.63 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 30 Sep 2026 | AUD 0.3900 |
| 2 Mar 2026 | AUD 0.3900 |
| 1 Oct 2025 | AUD 0.3300 |
| 4 Mar 2025 | AUD 0.3000 |
| 25 Sep 2024 | AUD 0.3300 |
| 4 Mar 2024 | AUD 0.3500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.